Sanofi

SNY

Market cap $115B

Overview Fund Activity

47.10 USD

+0.24

0.51%

At close Updated Sep 17, 11:13 AM EDT

1 day

0.51%

5 days

-0.36%

1 month

-5.5%

3 months

-2.32%

6 months

-20.06%

Year to date

-2.26%

1 year

-17.24%

5 years

-9.54%

10 years

-7.39%

About: Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Employees: 82,878

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

9% more call options, than puts

Call options by funds: $87.6M | Put options by funds: $80.3M

6% more repeat investments, than reductions

Existing positions increased: 270 | Existing positions reduced: 254

6% less funds holding

Funds holding: 756 [Q1] → 709 (-47) [Q2]

11.12% less ownership

Funds ownership: 21.06% [Q1] → 9.94% (-11.12%) [Q2]

18% less capital invested

Capital invested by funds: $14.4B [Q1] → $11.8B (-$2.61B) [Q2]

28% less first-time investments, than exits

New positions opened: 70 | Existing positions closed: 97

67% less funds holding in top 10

Funds holding in top 10: 12 [Q1] → 4 (-8) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$58

23% upside

Avg. target

$58

23% upside

High target

$58

23% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley

Mark Purcell

$58

Overweight

Upgraded

8 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 21 articles about SNY published over the past 30 days

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo at week 16 Dual-target Nanobody® VHH inhibiting TNF and OX40L being explored across a range of immune-mediated diseases Reaffirms Sanofi's commitment to addressing underlying inflammation across complex, heterogeneous chronic skin diseases Paris, September 17, 2025. New data from the HS-OBTAIN phase 2a study (clinical study identifier: NCT05849922) show that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS).

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

Zacks Investment Research

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degeneration Neovascular or “wet” age-related macular degeneration can lead to significant vision loss and affects more than one million people in the US Paris, September 11, 2025. The US Food and Drug Administration (FDA) has granted fast track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD).

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, according to an analysis by brokerage Morningstar.

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

Mandy Moore joins Elaine Welteroth, Gaby Dalkin, Katya Echazarreta, and Shawn Johnson East to share their personal respiratory syncytial virus (RSV) stories and why they chose BEYFORTUS to help protect their babies from serious RSV lung infection They join the millions of parents in the US who have chosen BEYFORTUS to help protect their babies from RSV, the number one reason babies under 1 are hospitalized MORRISTOWN, N.J. , Sept. 10, 2025 /PRNewswire/ -- Sanofi is partnering with celebrity moms who chose to immunize their babies with BEYFORTUS® (nirsevimab-alip) to help educate families about the importance of RSV infant protection.

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sanofi (NASDAQ:SNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Paul Hudson - CEO & Director Conference Call Participants Sarita Kapila - Morgan Stanley, Research Division Presentation Sarita Kapila Equity Analyst Okay. Perfect. Let's get started.

Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sanofi market value tanks following weak results on eczema drug trials

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab disappointed Wall Street.

Sanofi market value tanks following weak results on eczema drug trials

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA SNY stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company's ability to sustain its dermatology franchise once patent protections expire.

Why Is Sanofi Stock Falling Thursday?

Zacks Investment Research

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

See News Rankings

Charts implemented using Lightweight Charts™